Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

1.16
+0.04433.96%
Volume:616.46K
Turnover:705.50K
Market Cap:106.97M
PE:-4.05
High:1.23
Open:1.12
Low:1.12
Close:1.12
52wk High:1.55
52wk Low:0.4900
Shares:91.88M
Float Shares:39.87M
Volume Ratio:2.13
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2878
EPS(LYR):-0.4575
ROE:-33.68%
ROA:-22.81%
PB:1.46
PE(LYR):-2.54

Loading ...

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17

Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials

Reuters
·
Nov 07

Context Therapeutics Reports Improved Quarterly Results

TIPRANKS
·
Nov 06

Context Therapeutics reports Q3 results and advances lead bispecific antibody trials

Reuters
·
Nov 06

Context Therapeutics Inc. Q3 Basic EPS USD -0.1

THOMSON REUTERS
·
Nov 06

Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study

TIPRANKS
·
Oct 28

BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing

Reuters
·
Oct 25

Context Therapeutics: Amends Sales Agreement, May Offer & Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing

THOMSON REUTERS
·
Oct 25

Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025

Reuters
·
Oct 06

BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Oct 04

Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule

Reuters
·
Oct 04

Context Therapeutics Gains 11%, Insider Trades Reap Benefit

Simply Wall St.
·
Oct 03

Context Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Sep 18

Context Therapeutics Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Reuters
·
Sep 02

Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $4 From $5

THOMSON REUTERS
·
Aug 07

Context Therapeutics Q2 net loss widens, cash funds ops into 2027

Reuters
·
Aug 07

Context Therapeutics Inc - Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027

THOMSON REUTERS
·
Aug 07

Context Therapeutics Inc. Q2 Basic EPS USD -0.09

THOMSON REUTERS
·
Aug 07